AmCad BioMed Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yi-Li Lee

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.5yrs

Jüngste Management Updates

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

Geschäftsführer

Yi-Li Lee

no data

Amtszeit

NT$146,000

Vergütung

Ms. Yi-Li Lee serves as Chairman and President at AmCad BioMed Corporation. She serves as Vice President of Credit Agricole Corporate and Investment Bank. Ms. Lee serves as Senior Deputy General Manager of...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yi-Li Lee	Chairman & President	no data	NT$146.00k	keine Daten
Chen-Chia Lee	Director	no data	keine Daten	keine Daten
Yujia Li	Supervisor	no data	NT$45.00k	keine Daten
Jinjian Zhang	Supervisor	no data	NT$45.00k	4.58% NT$ 60.4m
Junheng Liao	Supervisor	no data	NT$25.00k	keine Daten
Weng-Foung Huang	Independent Director	no data	keine Daten	keine Daten
Yi-Ling Lee	Vice Chairman	4yrs	keine Daten	keine Daten
Tsay-Ping Wang	Director	1.5yrs	keine Daten	keine Daten
She-Yi Lin	Independent Director	1.5yrs	keine Daten	keine Daten
Hsueh-Yu Li	Independent Director	1.5yrs	keine Daten	keine Daten

1.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: 4188Die Vorstandsmitglieder gelten nicht als erfahren ( 1.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

AmCad BioMed Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: NT$0.30 loss per share (vs NT$0.20 loss in 3Q 2023)

AmCad BioMed Corporation to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.24 loss in 2Q 2023)

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation to Report Q2, 2024 Results on Aug 08, 2024

AmCad BioMed Corporation has completed a Follow-on Equity Offering in the amount of TWD 230 million.

First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.20 loss in 1Q 2023)

AmCad BioMed Corporation has filed a Follow-on Equity Offering in the amount of TWD 350 million.

AmCad BioMed Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$0.85 loss per share (vs NT$1.01 loss in FY 2022)

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.24 loss per share (vs NT$0.22 loss in 2Q 2022)

New minor risk - Share price stability

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.27 loss per share (vs NT$0.001 profit in 3Q 2021)

Second quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.16 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.15 loss per share (vs NT$0.21 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AmCad BioMed Corporation Appoints Maureen Chang as Spokesperson, Financial Officer and Accounting Officer

Third quarter 2021 earnings released: EPS NT$0.001 (vs NT$0.18 loss in 3Q 2020)

AmCad BioMed Corporation Announces Receiving FDA Approval of AmCad UTdeep Learning Advanced Version

Second quarter 2021 earnings released: NT$0.16 loss per share (vs NT$0.10 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.21 loss per share (vs NT$0.30 loss in 1Q 2020)

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

AmCad BioMed Corporation, Annual General Meeting, May 21, 2021

New 90-day low: NT$18.55

New 90-day low: NT$18.80

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Third quarter 2020 earnings released: NT$0.19 loss per share

AmCad BioMed Corporation Announces Board Changes

AmCad BioMed Corporation Announces Resignation of Lee, Chen Chia as Chairperson, Effective November 5, 2020

New 90-day low: NT$19.45

First half earnings released

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit